ICD Research's ImmunoGen, Inc. : Pharmaceuticals and Healthcare - Company Profile, SWOT & Financial Report contains in depth information and data about the company and its operations. The profile contains a company overview, key facts, major products and services, swot analysis, business description, company history, financial analysis, mergers & acquisitions, recent developments, key employees, company locations and subsidiaries, employee biographies as well as competitive benchmarking data.
This report is a crucial resource for industry executives and anyone looking to access key information about ImmunoGen, Inc.
The report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. ICD Research strictly follows a standardized research methodology to ensure high levels of data quality and these characteristics guarantee a unique report.
Examines and identifies key information and issues about ImmunoGen, Inc. for business intelligence requirements.
Studies and presents the company's strengths, weaknesses, opportunities (growth potential) and threats (competition). Strategic and operational business information is objectively reported.
Provides data on company financial performance and competitive benchmarking.
The profile also contains information on business operations, company history, major products and services, key employees, locations and subsidiaries.
Reasons To Buy
Quickly enhance your understanding of ImmunoGen, Inc.
Gain insight into the marketplace and a better understanding of internal and external factors which could impact the industry.
Increase business/sales activities by understanding your competitors’ businesses better.
Recognize potential partnerships and suppliers.
ImmunoGen, Inc. (ImmunoGen) is a biopharmaceutical company specialized in the development of anticancer therapeutics. The company's TAP technology uses monoclonal antibodies to produce proprietary cancer-cell killing agents to tumor cells. Its TAP technology is designed to deliver the creation of well-tolerated anticancer products. The company also licenses TAP technology to various other companies including Amgen, Lilly, Bayer HealthCare, Biotest, Novartis, Roche and Sanofi, which use its proprietary antibodies to specific targets. As of June 30, 2012, the company had a patent portfolio of 381 issued patents and 438 pending patent applications. ImmunoGen is headquartered in Waltham, Massachusetts, the US.